243 related articles for article (PubMed ID: 37642362)
1. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
Bireley JD; Morren JA
Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
[TBL] [Abstract][Full Text] [Related]
2. Study protocol of RESCUE-ALS: A Phase 2,
Vucic S; Kiernan MC; Menon P; Huynh W; Rynders A; Ho KS; Glanzman R; Hotchkin MT
BMJ Open; 2021 Jan; 11(1):e041479. PubMed ID: 33431491
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.
Vucic S; Menon P; Huynh W; Mahoney C; Ho KS; Hartford A; Rynders A; Evan J; Evan J; Ligozio S; Glanzman R; Hotchkin MT; Kiernan MC
EClinicalMedicine; 2023 Jun; 60():102036. PubMed ID: 37396808
[TBL] [Abstract][Full Text] [Related]
4. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022.
Jiang J; Wang Y; Deng M
Front Pharmacol; 2022; 13():1054006. PubMed ID: 36518658
[TBL] [Abstract][Full Text] [Related]
5. Edaravone for the treatment of amyotrophic lateral sclerosis.
Yoshino H
Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
[TBL] [Abstract][Full Text] [Related]
6. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Jaiswal MK
Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
[TBL] [Abstract][Full Text] [Related]
7. Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
Pattee GL; Genge A; Couratier P; Lunetta C; Sobue G; Aoki M; Yoshino H; Jackson CE; Wymer J; Salah A; Nelson S
Expert Rev Neurother; 2023; 23(10):859-866. PubMed ID: 37646130
[TBL] [Abstract][Full Text] [Related]
8. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
Dash RP; Babu RJ; Srinivas NR
Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
Sun Y; Li X; Bedlack R
Expert Rev Neurother; 2023 Jan; 23(1):1-7. PubMed ID: 36705941
[TBL] [Abstract][Full Text] [Related]
10. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Bhandari R; Kuhad A; Kuhad A
Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
[TBL] [Abstract][Full Text] [Related]
11. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
12. Disease-modifying treatment of amyotrophic lateral sclerosis.
Schultz J
Am J Manag Care; 2018 Aug; 24(15 Suppl):S327-S335. PubMed ID: 30207671
[TBL] [Abstract][Full Text] [Related]
13. Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis.
Hergesheimer R; Lanznaster D; Vourc'h P; Andres C; Bakkouche S; Beltran S; Blasco H; Corcia P; Couratier P
Expert Opin Pharmacother; 2020 Jun; 21(9):1103-1110. PubMed ID: 32242755
[TBL] [Abstract][Full Text] [Related]
14. [Drugs for Amyotrophic Lateral Sclerosis].
Ogino M
Brain Nerve; 2023 May; 75(5):503-506. PubMed ID: 37194520
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
Johnson SA; Fang T; De Marchi F; Neel D; Van Weehaeghe D; Berry JD; Paganoni S
Drugs; 2022 Sep; 82(13):1367-1388. PubMed ID: 36121612
[TBL] [Abstract][Full Text] [Related]
16. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
Singh P; Belliveau P; Towle J; Neculau AE; Dima L
Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
[TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
Noto Y; Shibuya K; Vucic S; Kiernan MC
Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
[TBL] [Abstract][Full Text] [Related]
20. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]